Rocketlane Medical Ventures

What Rocketlane Medical Ventures does

Rocketlane Medical Ventures GmbH (RLMV) is a Germany-based digital health company founded in 2020 in Dresden as the digital subsidiary of pharmaceutical group APOGEPHA Arzneimittel GmbH. The company develops Digital Therapeutics (DTx) — software-based medical treatments certified as medical devices — focused initially on urology, specifically the pre- and post-operative care of patients undergoing prostate surgery. Its flagship product, the Uroletics app, is registered with the German Federal Institute for Drugs and Medical Devices (BfArM) for the prevention and therapy of erectile dysfunction and incontinence around prostate interventions.

The Uroletics platform is a mobile application (iOS and Android) combined with a knowledge portal and an incontinence store. It delivers 3D-guided pelvic floor training, perioperative psycho-oncological mental coaching, a postoperative complication radar, and PSA follow-up tracking, with structured clinical endpoint measurement (e.g., IIEF-5, Pad-Test) that feeds automated treatment reports back to outpatient urologists. The product was developed by university hospital physicians in collaboration with physiotherapists, and was launched commercially in April 2021.

RLMV operates a hybrid go-to-market: consumer-facing product-led growth via app store distribution, combined with B2B selective contracts (Selektivverträge) with private health insurers — notably Barmenia from March 2022, with Allianz also referenced as a partner — enabling direct reimbursement for insured patients. Revenue mechanics therefore combine direct self-pay app sales with insurer-covered subscription access for prostate carcinoma patients. The company has a team of over 50 employees across Dresden, Munich, Berlin, Ukraine, and the United States, with disclosed funding limited to a 2021 non-dilutive grant from the Bavarian State Ministry of Economic Affairs.

Name

Rocketlane Medical Ventures

Legal name

Rocketlane Medical Ventures GmbH

Website

https://rocketlane.de

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Rocketlane Medical Ventures develops BfArM-certified Digital Therapeutics, anchored by its Uroletics app that delivers pre- and post-operative digital therapy for prostate surgery patients in Germany via health insurer reimbursement and direct app store distribution.

Ownership category

akta.pro rank

Product category

Digital Therapeutics (Digital Health)

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000)

akta.pro primary industry

Urologic Oncology (HLAKAOAB)

akta.pro secondary industry

Surgical, Perioperative & ERAS Pathway Tools (HLACAGAJ)

Keywords

• Digital therapeutics software
• Medical mobile applications
• Pelvic floor training
• Prostate care platform
• Digital health software

Headquarters

HQ city

Dresden

HQ country

Germany

HQ region

Europe

Offices5 records

Markets served

GTM type

B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Digital Therapeutics App Sales: Direct sales of Uroletics app to patients, with reimbursement coverage through selective contracts with private health insurers such as Barmenia.
2. Health Insurance Reimbursement: Revenue through selective contracts (Selektivverträge) with private health insurance companies like Barmenia that cover the Uroletics app for patients with prostate carcinoma.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Rocketlane Medical Ventures develops and distributes the Uroletics digital therapeutics platform — a BfArM-certified medical-device mobile application that provides pre- and post-operative digital care for patients undergoing prostate surgery. The offering includes 3D-guided pelvic floor training, perioperative psycho-oncological mental coaching, post-operative complication monitoring, and PSA follow-up functionality, delivered via consumer mobile apps and reimbursed through selective contracts with private health insurers such as Barmenia.

Product overview

Rocketlane Medical Ventures (RLMV), the digital subsidiary of APOGEPHA Arzneimittel GmbH, develops Digital Therapeutics (DTx) for the German healthcare market. The company operates primarily through its Uroletics product — a comprehensive digital therapy platform for urology patients. Uroletics consists of a mobile application (available on iOS and Android) designed for patients undergoing prostate surgery, providing 3D pelvic floor training, mental coaching, complication monitoring, and PSA follow-up features. The platform is complemented by a knowledge portal (Wissensplattform) and an incontinence store, collectively forming a digital patient companion that connects outpatient urologists with clinical care.

Differentiator

Problem solved

Functional benefit

Brands

• Uroletics: Digital Therapeutics app for prostate care featuring 3D pelvic floor coaching, mental coaching, and PSA follow-up. Approved by BfArM for prevention and therapy of erectile dysfunction and incontinence before and after prostate interventions.

Products and services

• Uroletics A Digital Therapeutics (DTx) mobile application designed for pre- and post-operative care for patients undergoing prostate surgery. Provides 3D pelvic floor training, perioperative psycho-oncological mental coaching, post-operative complication radar, and PSA follow-up functionality. Registered as a medical device with BfArM for prevention and therapy of erectile dysfunction and incontinence, particularly before and after prostate interventions.

Quantifiable outcome

• 2858 publications on DTx topic worldwide in 2022 - growing evidence base for digital therapeutics
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Barmenia Private KrankenversicherungcoreChannel Partner/ Reseller/ Distributor · 11 March 2022Selective contract (Selektivvertrag) with Barmenia Private Krankenversicherung. Barmenia actively supports patients with prostate carcinoma by offering the Uroletics app for prehabilitation and rehabilitation. This creates an important milestone for men's medicine.
• APOGEPHA Arzneimittel GmbHcoreStrategic or Co-development Partner · 1 January 2020APOGEPHA Arzneimittel GmbH is the parent company of Rocketlane. RLMV is the digital subsidiary (Digitaltochter) of APOGEPHA. The team consists of experts from all areas of research and development as well as medicine who contribute their expertise to the development of digital products.
• AllianzminorChannel Partner/ Reseller/ DistributorHealth insurance partner shown in logo section. Partnership enables reimbursement coverage for insured patients.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vivira Health Lab: German DiGA-listed digital therapeutics provider; comparable as a certified digital therapeutic reimbursed through statutory and private payors in Germany, using a similar app-based, prescription-driven model.
• Kaia Health: Digital therapeutics company delivering evidence-based app therapy for musculoskeletal conditions; comparable as a certified DTx sold direct-to-patient and reimbursed through payor partnerships in Europe.
• Selfapy: Berlin-based DiGA provider offering reimbursed digital therapeutic courses (mental health, burnout); comparable as a German-certified DTx commercialized via selective contracts with statutory and private insurers.
• HelloBetter: German DiGA provider of digital mental health interventions; comparable as a certified, evidence-based digital therapeutic sold through payor reimbursement channels in Germany.
• Aidin Technologies (Aidhere): Hamburg-based DiGA provider (Zanadio) for obesity and adjacent conditions; comparable as a German DTx operating under BfArM/DiGA frameworks with payor reimbursement models similar to Uroletics.
• Newsenselab (m-Sense): German DTx/digital health company focused on migraine management via a certified medical app; comparable as a BfArM-cleared app-based therapy commercialized through German payors.
• Perfood: German digital therapeutics company offering certified nutrition-based DTx for conditions like migraine and depression; comparable as a BfArM-recognized DTx commercialized via payor reimbursement in Germany.

Emerging players

• Sidekick Health: Digital therapeutics platform addressing chronic and lifestyle conditions via app-based care; comparable as an emerging European DTx commercializing into urology/cardio/metabolic adjacencies with payor channels.

Broad incumbents

• Philips (Digital Health): Large medical technology incumbent with a portfolio of connected care, telehealth, and digital health offerings; comparable as a broad incumbent exploring digital therapeutic adjacencies including urology.

Others

• Doxy.me / Klara: Telehealth and patient-communication infrastructure providers used by urologists and other specialists; comparable as adjacent digital-health enablers supporting the same outpatient-urologist workflow that Uroletics plugs into.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/rocketlane-medical-ventures-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rocketlane Medical Ventures